Cargando…
Reply to F. Muntoni et al.: “In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
IOS Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657699/ https://www.ncbi.nlm.nih.gov/pubmed/37955094 http://dx.doi.org/10.3233/JND-239005 |
| _version_ | 1785148194500378624 |
|---|---|
| author | Clemens, Paula R. Hoffman, Eric P. |
| author_facet | Clemens, Paula R. Hoffman, Eric P. |
| author_sort | Clemens, Paula R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10657699 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | IOS Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106576992023-11-19 Reply to F. Muntoni et al.: “In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy Clemens, Paula R. Hoffman, Eric P. J Neuromuscul Dis Reply to the Letter to the Editor IOS Press 2023-11-07 /pmc/articles/PMC10657699/ /pubmed/37955094 http://dx.doi.org/10.3233/JND-239005 Text en © 2023 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Reply to the Letter to the Editor Clemens, Paula R. Hoffman, Eric P. Reply to F. Muntoni et al.: “In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy |
| title | Reply to F. Muntoni et al.: “In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy |
| title_full | Reply to F. Muntoni et al.: “In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy |
| title_fullStr | Reply to F. Muntoni et al.: “In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy |
| title_full_unstemmed | Reply to F. Muntoni et al.: “In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy |
| title_short | Reply to F. Muntoni et al.: “In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy |
| title_sort | reply to f. muntoni et al.: “in response to p.r. clemens et al., efficacy and safety of viltolarsen in boys with duchenne muscular dystrophy: results from the phase 2, open-label, 4-year extension study, and long-term functional efficacy and safety of viltolarsen in patients with duchenne muscular dystrophy |
| topic | Reply to the Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657699/ https://www.ncbi.nlm.nih.gov/pubmed/37955094 http://dx.doi.org/10.3233/JND-239005 |
| work_keys_str_mv | AT clemenspaular replytofmuntonietalinresponsetoprclemensetalefficacyandsafetyofviltolarseninboyswithduchennemusculardystrophyresultsfromthephase2openlabel4yearextensionstudyandlongtermfunctionalefficacyandsafetyofviltolarseninpatientswithduchennemusculardystrophy AT hoffmanericp replytofmuntonietalinresponsetoprclemensetalefficacyandsafetyofviltolarseninboyswithduchennemusculardystrophyresultsfromthephase2openlabel4yearextensionstudyandlongtermfunctionalefficacyandsafetyofviltolarseninpatientswithduchennemusculardystrophy |